Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...

Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

We’re in the midst of a paradigm shift in biomarker science. | The right biomarker signature can de-risk trials, guide ...

Chugai, a Japanese company majority owned by Roche, has identified Gero’s platform as complementary to its own capabilities.

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch ...